If proven safe and effective throughout the remaining stages of research, segesterone acetate (SGA) could be one of the first remyelination therapies approved to treat multiple sclerosis. The project is supported in part by the National Multiple Sclerosis Society’s commercial development program, Fast Forward, LLC.